Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embracing Early-Stage Platform Opportunities at Polaris Ventures

This article was originally published in Start Up

Executive Summary

In an interview with START-UP, Polaris Ventures managing partner Terry McGuire discusses recent investment opportunities and his firm's approach to platform technologies in the life sciences. Topics covered include: diagnostics, community diseases, next-generation biologics, and fund diversification.

You may also be interested in...



Polaris Partners: The 2013 A-List Investor Spotlight

Polaris’ focus on people and platforms was never more evident than in 2013, when it leveraged its relationship with one entrepreneur in particular to great effect.

Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal

Takeda gains non-exclusive access to Alnylam’s RNAi therapeutics platform in oncology and metabolic disease for $150 million upfront.

Sirtris Satisfies GSK's M&A Appetite

Pathway-oriented platforms are rare, and dealmaking around them can be complicated: partner too early or for too little and you risk giving away the store. But Sirtris pulled it off, via M&A, when GSK tendered a whopping $720 million for it in April. The deal is another example of Pharma's interest in platform biotechs and its hunger for innovation. But the unique nature of Sirtris's platform -- broad, but around a single set of biological targets -- makes it more one-off than trend-setting.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091362

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel